Literature DB >> 10408359

Predictivity of an in vitro model for acute and chronic skin irritation (SkinEthic) applied to the testing of topical vehicles.

V Picarles, S Chibout, M Kolopp, J Medina, P Burtin, M E Ebelin, S Osborne, F K Mayer, A Spake, M Rosdy, B De Wever, R A Ettlin, A Cordier.   

Abstract

An in vitro human reconstructed epidermis model (SkinEthic) used for screening acute and chronic skin irritation potential was validated against in vivo data from skin tolerability studies. The irritation potential of sodium lauryl sulfate (SLS), calcipotriol and trans-retinoic acid was investigated. The in vitro epidermis-like model consists of cultures of keratinocytes from human foreskin on a polycarbonate filter. The modulation of cell viability, the release and gene expression of proinflammatory cytokines, interleukins 1alpha and 8, and morphological changes were evaluated during 3 days as endpoints representative for an inflammatory reaction. The cumulative irritation potential of the topical products was evaluated in a human clinical study by visual scoring and biophysical measurement of inflammatory skin reaction after repeated 24 h applications over 3 weeks under Finn chamber patches. All topical products that were nonirritating in the human study were noncytotoxic and did not induce cytokine expression in the in vitro acute model (day 1 exposure). All irritating controls exhibited specific cell viability and cytokine patterns, which were predictive of the in vivo human data. The ranking of mild to moderate skin irritation potential was based on the lack of cytotoxicity and the presence of cytokine patterns including gene expression specific for each irritant, using the chronic in vitro model (up to 3 days exposure). The human reconstructed epidermis model SkinEthic was shown to be a reliable preclinical tool predicting the irritation potential of topical products. Moreover, it is a useful model in a two-step tiered strategy for screening acute and chronic irritation potential for the selection of vehicles for new topical drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408359     DOI: 10.1023/a:1007577515215

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  6 in total

1.  Development of a highly reproducible three-dimensional organotypic model of the oral mucosa.

Authors:  Anna Dongari-Bagtzoglou; Helena Kashleva
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 2.  Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications.

Authors:  Sana Suhail; Naseem Sardashti; Devina Jaiswal; Swetha Rudraiah; Manoj Misra; Sangamesh G Kumbar
Journal:  Biotechnol J       Date:  2019-05-17       Impact factor: 4.677

3.  Kinetic analysis on the skin disposition of cytotoxicity as an index of skin irritation produced by cetylpyridinium chloride: comparison of in vitro data using a three-dimensional cultured human skin model with in vivo results in hairless mice.

Authors:  Satoshi Kano; Kenji Sugibayashi
Journal:  Pharm Res       Date:  2006-02-02       Impact factor: 4.200

Review 4.  Alternatives to In Vivo Draize Rabbit Eye and Skin Irritation Tests with a Focus on 3D Reconstructed Human Cornea-Like Epithelium and Epidermis Models.

Authors:  Miri Lee; Jee-Hyun Hwang; Kyung-Min Lim
Journal:  Toxicol Res       Date:  2017-07-15

5.  Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models.

Authors:  Jos P H Smits; Hanna Niehues; Gijs Rikken; Ivonne M J J van Vlijmen-Willems; Guillaume W H J F van de Zande; Patrick L J M Zeeuwen; Joost Schalkwijk; Ellen H van den Bogaard
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

Review 6.  Development of Skin-On-A-Chip Platforms for Different Utilizations: Factors to Be Considered.

Authors:  J Ponmozhi; S Dhinakaran; Zsófia Varga-Medveczky; Katalin Fónagy; Luca Anna Bors; Kristóf Iván; Franciska Erdő
Journal:  Micromachines (Basel)       Date:  2021-03-10       Impact factor: 2.891

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.